SALT LAKE CITY, Jan. 09, 2026 — Leads & Copy — Clene Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., announced a registered direct offering priced above market of over $28 million. The financing, through its three tranches, is expected to provide the Company with sufficient capital into early 2027, which is expected to allow potential commercialization of CNM-Au8 in ALS.
The initial financing tranche is over $6 million, which Clene expects will provide cash runway into the third quarter of 2026, enabling funding through potential NDA acceptance decision by the FDA. Two additional financing tranches totaling over $22 million are contingent on NDA acceptance and NDA approval by the FDA.
Clene entered into securities purchase agreements on January 9, 2026, for the issuance and sale of 928,333 shares of common stock and accompanying warrants at an offering price of $6.50 per unit for each investor, totaling $6.03 million of gross proceeds. These proceeds are expected to fund Clene into the third quarter of 2026.
The agreements also include Series A Warrants, which entitle each purchaser to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price. Each Series A Warrant will have an initial exercise price of $6.00 per share and will be exercisable immediately upon issuance.
The exercise price of each Series A Warrant will increase to $7.00 per share if either: (a) the warrant is exercised prior to the Company’s public announcement of the FDA’s posted PDUFA action date for the CNM-Au8 NDA (expected in the first quarter of 2026); or (b) the volume-weighted average price of the Company’s common stock equals or exceeds $10.00 on the measurement date associated with the PDUFA Date Announcement.
Potential gross proceeds from the exercise of the Series A Warrants totals approximately $6.7 million and is expected to fund the Company through the end of 2026.
Series B Warrants entitle each purchaser to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price. Each Series B Warrant will have an initial exercise price of $6.00 per share and will be exercisable immediately upon issuance.
The exercise price of each Series B Warrant is subject to increase based on the timing of exercise and the common stock’s volume-weighted average price in connection with the Company’s public announcement of its receipt of written FDA approval for the CNM-Au8 NDA in ALS.
The exercise price will increase to $12.50 per share if the Series B Warrant is exercised before the FDA Approval Announcement. If exercised after the FDA Approval Announcement, it will increase to: (a) $10.00 per share, if the volume-weighted average price of Clene’s common stock on Nasdaq is equal to or greater than $20.00 on the measurement date associated with the FDA Approval Announcement or (b) $12.50 share if the volume-weighted average price of Clene’s common stock on Nasdaq is equal to or greater than $25.00 on the measurement date.
Potential gross proceeds from the exercise of the Series B Warrants totals approximately $15.6 million and is expected to fund the Company’s commercialization efforts.
Clene may redeem or call the Series A Warrants and the Series B Warrants for cancellation if the closing price of the Company’s common stock exceeds the then-effective exercise price on or after the applicable measurement date. In such case, the Company will have seven business days to exercise this right. On the Call Date, all unexercised warrants will be automatically redeemed by the Company for $0.01 per share. Subject to this redemption right, the Series A Warrants expire three years from issuance and the Series B Warrants expire five years from issuance.
BTIG, LLC is acting as sole placement agent for the offering, which is expected to close on or about January 12, 2026.
Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization.
“We are happy to welcome top-tier investors Boxer Capital, Coastlands Capital and Vivo Capital, along with other current insider investors, who share our excitement and enthusiasm for the important work that Clene has undertaken in ALS,” said Rob Etherington, CEO of Clene, Inc.
Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; 617-283-2856
Source: Clene Inc.
